Cardiac Dimensions has received CE mark approval for its carillon mitral contour system, a novel therapy for treating heart failure patients suffering from functional mitral regurgitation (FMR).
The mitral contour system consists of a proprietary, implantable device with a percutaneous catheter delivery system.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The approval is backed by Amadeus and Titan clinical trials of the Carillon system, which demonstrated reduction in FMR and improvement in functional capacity and quality of life.
Another study, called Titan II, was recently initiated to further the clinical experience.
Commercial launch of the device in Europe will begin in 2012, the company said.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
